Vaddi Krishna 4

What Happened Vaddi Krishna, CEO and Director of Prelude Therapeutics (PRLD), was granted a derivative award covering 837,000 shares on Feb 4, 2026. The award is reported at $0.00 per share (no cash payment recorded) and is a service‑based equity grant rather than an open‑market purchase or sale.

Key Details

• Transaction date: February 4, 2026; Form 4 filed February 5, 2026 (appears timely).
• Grant type: Derivative award (stock option/equity award) for 837,000 shares, recorded at $0.00 per share.
• Shares owned after transaction: Not stated in the provided filing details.
• Footnote: The award vests 25% on Feb 4, 2027, then vests monthly at 1/48 of the total shares thereafter until fully vested, contingent on continued service.
• No indication of sales, tax withholding, or a 10b5-1 plan in the provided data.

Context This filing documents a standard equity grant to the CEO that vests over time (typical four‑year schedule: 25% after one year, then monthly vesting). Because it's an awarded derivative security (not an immediate purchase or sale), it reflects compensation/retention, not an immediate market transaction. Retail investors should view this as insider compensation disclosure; it does not by itself indicate the insider bought or sold shares on the open market.